Roche's anti-TIGIT drug suffers a phase III cancer setback

被引：6
|
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 05期
关键词：
D O I：
10.1038/d41573-022-00068-4
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [11] Zeneca and Roche promote anti-cancer drug
    不详
    CHEMISTRY IN BRITAIN, 1998, 34 (10) : 11 - 11
  • [12] Androgen deprivation therapy allows for effective anti-TIGIT immunotherapy in murine model of castration resistant prostate cancer
    Polesso, Fanny
    Guan, Xiangnan
    Xia, Zheng
    Moran, Amy E.
    CANCER RESEARCH, 2022, 82 (12)
  • [13] Roche halts antidiabetic's development in phase III
    Reactions Weekly, 2013, 1461 (1) : 4 - 4
  • [14] Phase 2 Platform Trial of Anti-TIGIT GSK'859A/EOS-448+Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
    Spigel, D.
    Lopez, P. G.
    Cheema, P.
    Garassino, M.
    Cousin, S.
    Gandhi, Y.
    Theti, D.
    Stylianou, A.
    Messina, C.
    Roy-Ghanta, S.
    Ballas, M.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S346 - S346
  • [15] Requirement of Fc gamma receptor-mediated myeloid-cell activation for effective cancer immunotherapy with an anti-TIGIT antibody
    Han, Jin-hwan
    Cai, Mingmei
    Grein, Jeffery
    Perera, Samanthi
    Wang, Hongmei
    Bigler, Mike
    Ueda, Roenna
    Rosahl, Thomas
    Pinheiro, Elaine
    LaFace, Drake
    Seghezzi, Wolfgang
    Williams, Sybil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [16] Androgen deprivation therapy allows for effective anti-TIGIT immunotherapy in murine model of castration resistant prostate cancer.
    Polesso, Fanny
    Guan, Xiangnan
    Xia, Zheng
    Moran, Amy E.
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01)
  • [17] Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1-Positive Metastatic NSCLC
    Hellmann, M. D.
    Cho, B. C.
    Juergens, R.
    Cheng, Y.
    De Castro, G., Jr.
    Erman, M.
    Bauman, J. R.
    Takahashi, T.
    Schwarzenberger, P.
    Zhang, P.
    Pietanza, M. C.
    Yang, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1010 - S1011
  • [18] Iniparib in Phase III - Significant Setback for Patients with Triple Negative Breast Cancer
    Liedtke, Cornelia
    BREAST CARE, 2011, 6 (04) : 321 - 322
  • [19] First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
    Niu, J.
    Maurice-Dror, C.
    Lee, D. H.
    Kim, D. -W.
    Nagrial, A.
    Voskoboynik, M.
    Chung, H. C.
    Mileham, K.
    Vaishampayan, U.
    Rasco, D.
    Golan, T.
    Bauer, T. M.
    Jimeno, A.
    Chung, V.
    Chartash, E.
    Lala, M.
    Chen, Q.
    Healy, J. A.
    Ahn, M. -J.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 169 - 180
  • [20] Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial
    Dummer, Reinhard
    Robert, Caroline
    Scolyer, Richard A.
    Taube, Janis M.
    Tetzlaff, Michael T.
    Menzies, Alexander M.
    Hill, Andrew
    Grob, Jean-Jacques
    Portnoy, David C.
    Lebbe, Celeste
    Khattak, Muhammad A.
    Cohen, Jonathan
    Bar-Sela, Gil
    Mehmi, Inderjit
    Shapira-Frommer, Ronnie
    Meyer, Nicolas
    Webber, Andrea L.
    Ren, Yixin
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Long, Georgina V.
    NATURE MEDICINE, 2025, 31 (01) : 144 - 151
12345